Samples of 27 drugs manufactured in Himachal found substandard

As many as 27 drug samples, manufactured at pharmaceutical units of Himachal Pradesh at Baddi, Nalagarh, Paonta Sahib, Kala Amb, Solan and Kangra, have been declared sub substandard by the Central Drugs Standard Control Organisation (CDSCO).

These figure among the list of 111 drug samples declared not of standard quality and the Central Drugs Standard Control Organization (CDSCO) has issued a drug alert regarding this.

The list released on December 27, is part of the continuous regulatory surveillance where drugs samples are picked from sales/distribution points and analysed.

CDSCO releases list of the medicines that do not meet the standards and in month of November a total of 111 drug samples failed. Out of these 27 drugs were manufactured in Himachal. Most of the these drugs are used in the treatment of heart diseases, high blood pressure, pain, antibiotics and other diseases, including allergies.

State drugs controller Manish Kapoor said they were closely regulating the manufacturing through regular inspections where compliance was ensured in firms lacking regulatory parameters.

He said about 142 companies have been ordered to stop manufacturing following certain flaws that were noticed during inspection. Kapoor said that action will be taken as per rules against the companies whose drug samples have failed. Notices have been issued to these drug companies.

Related Posts

  • Pharma
  • August 8, 2025
  • 469 views
Delhi Police busts major fake medicine racket; 6 arrested including kingpin

The Anti-Gang Squad of the Crime Branch of Delhi Police has busted a major interstate racket involved in the manufacturing, selling, and supplying of counterfeit lifesaving medicines. In this significant…

  • Pharma
  • August 8, 2025
  • 265 views
Indian Pharma Market grows by 7.9% in July; antibiotic Augmentin rebounds to top spot

New Delhi: The Indian Pharmaceutical Market (IPM) in July underwent a value growth of 7.9 per cent driven by new launches in the anti-diabetic segment and value growth of cardiac…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Govt Temporarily Eases BIS Rules for Medical Device Parts

Biocon Bets Big on Insulin, Eyes GLP-1 Drugs for Future Growth

Biocon Bets Big on Insulin, Eyes GLP-1 Drugs for Future Growth

Delhi Police busts major fake medicine racket; 6 arrested including kingpin

Delhi Police busts major fake medicine racket; 6 arrested including kingpin

Indian Pharma Market grows by 7.9% in July; antibiotic Augmentin rebounds to top spot

Indian Pharma Market grows by 7.9% in July; antibiotic Augmentin rebounds to top spot